Sinopharm COVID-19 booster weaker against Omicron — study | Inquirer News
Close  

Sinopharm COVID-19 booster weaker against Omicron — study

/ 05:45 PM December 20, 2021
FILE PHOTO: A logo of Sinopharm is pictured during a government-organised visit to the production line of COVID-19 vaccine by Beijing Institute of Biological Products of Sinopharm's China National Biotec Group (CNBG), in Beijing, China February 26, 2021. REUTERS/Tingshu Wang

FILE PHOTO: A logo of Sinopharm is pictured during a government-organized visit to the production line of COVID-19 vaccine by Beijing Institute of Biological Products of Sinopharm’s China National Biotec Group (CNBG), in Beijing, China February 26, 2021. REUTERS/Tingshu Wang

BEIJING — A COVID-19 booster shot produced by China’s Sinopharm had “significantly lower” neutralizing activity against the Omicron variant, Chinese researchers said in a paper, although they added the vaccine’s efficacy against Omicron remained unclear.

The study – conducted by researchers from Shanghai Jiao Tong University and a Shanghai-based lab specializing in respiratory infectious diseases – compared the activity of Sinopharm’s booster vaccine against an older coronavirus strain from Wuhan.

ADVERTISEMENT

The neutralizing antibody activity of a Sinopharm BBIBP-CorV booster against Omicron showed a 20.1-fold reduction, compared with its activity against a Wuhan strain, according to the paper published on Saturday.

Sinopharm did not immediately respond to a request for comment.

FEATURED STORIES

Sinopharm’s BBIBP-CorV vaccine and Sinovac Biotech’s CoronaVac are the two most used vaccines in China and are the leading COVID-19 vaccines exported by the country. Sinopharm also has a second vaccine in use in China.

The study analyzed samples from 292 healthcare workers who received a third dose, or booster shot, about eight to nine months after their second dose. After a further four weeks, serum samples from 78.1% participants retained neutralizing activity against Omicron, researchers said in a paper that has not been peer reviewed.

However, the study authors cautioned the results were not equal to how well a Sinopharm booster could shield recipients from diseases caused by Omicron, as neutralization is only part of the human immune response.

The testing against the earlier Wuhan strain showed that about eight to nine months after the second BBIBP-CorV shot, the neutralizing activity “could hardly be detected”, while the booster lifted the response significantly, according to the paper.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.
Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: China, coronavirus vaccines, COVID-19 vaccine booster shot, Omicron variant, Sinopharm
For feedback, complaints, or inquiries, contact us.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.



© Copyright 1997-2022 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.